Table 2.
Mean annual total cost (US $) per treated patient
| Indication | ABA (N = 583) | ADA (N = 6521) | CER (N = 415) | ETN (N = 9116) | GOL (N = 231) | INF (N = 1906) | RIT (N = 295) | TOC (N = 165) | TOF (N = 5) | UST (N = 922) |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | ||||||||||
| RA only | $21,877 | $30,269 | $26,285 | $25,805 | $27,666 | $26,370 | $19,569 | $23,682 | $18,769 | NA |
| PsO only | NA | $29,186 | NA | $31,212 | NA | $32,409 | NA | NA | NA | $53,746 |
| PsA only | NA | $28,749 | NA | $26,916 | $27,987 | $31,974 | NA | NA | NA | NA |
| AS only | NA | $28,558 | NA | $25,131 | $24,225 | $29,568 | NA | NA | NA | NA |
| RA/PsA only | NTP | $28,984 | NTP | $25,477 | $26,641 | $29,760 | NTP | NTP | NTP | NA |
| PsO/PsA only | NA | $29,508 | NA | $29,376 | NTP | $34,541 | NA | NA | NA | NTP |
| All other combinations | NTP | $28,129 | NTP | $26,543 | $28,988 | $31,972 | NTP | NTP | NTP | NTP |
| Across indications | NA | $29,521 | NA | $27,488 | NA | $28,672 | NA | NA | NA | NA |
| Patients new to biologics | ||||||||||
| RA only | $20,774 | $26,246 | $24,558 | $24,452 | $25,857 | $23,205 | $18,353 | $21,666 | $18,769 | NA |
| PsO only | NA | $28,197 | NA | $32,030 | NA | $34,690 | NA | NA | NA | $55,457 |
| PsA only | NA | $24,610 | NA | $25,780 | $29,631 | $28,514 | NA | NA | NA | NA |
| AS only | NA | $24,936 | NA | $22,861 | $22,271 | $28,951 | NA | NA | NA | NA |
| RA/PsA only | NTP | $20,950 | NTP | $22,828 | $29,353 | $21,228 | NTP | NTP | NTP | NA |
| PsO/PsA only | NA | $27,823 | NA | $29,405 | NTP | $29,376 | NA | NA | NA | NTP |
| All other combinations | NTP | $24,467 | NTP | $25,669 | $32,207 | $25,655 | NTP | NTP | NTP | NTP |
| Across indications | NA | $26,681 | NA | $27,063 | NA | $25,316 | NA | NA | NA | NA |
| Continuing users | ||||||||||
| RA only | $22,246 | $31,931 | $28,253 | $26,472 | $28,632 | $27,184 | $22,475 | $24,926 | NTP | NA |
| PsO only | NA | $29,728 | NA | $30,650 | NA | $31,696 | NA | NA | NA | $52,321 |
| PsA only | NA | $30,273 | NA | $27,420 | $27,069 | $32,560 | NA | NA | NA | NA |
| AS only | NA | $30,594 | NA | $26,262 | $26,180 | $29,824 | NA | NA | NA | NA |
| RA/PsA only | NTP | $32,700 | NTP | $27,049 | $25,284 | $30,719 | NTP | NTP | NTP | NA |
| PsO/PsA only | NA | $30,389 | NA | $29,354 | NTP | $36,133 | NA | NA | NA | NTP |
| All other combinations | NTP | $30,036 | NTP | $27,113 | $25,768 | $33,920 | NTP | NTP | NTP | NTP |
| Across indications | NA | $30,856 | NA | $27,726 | NA | $29,541 | NA | NA | NA | NA |
ABA abatacept, ADA adalimumab, AS ankylosing spondylitis, CER certolizumab pegol, ETN etanercept, GOL golimumab, INF infliximab, NA not approved, NTP no treated patients, PsA psoriatic arthritis, PsO psoriasis, RA rheumatoid arthritis, RIT rituximab, TOC tocilizumab, TOF tofacitinib, UST ustekinumab